Allogene Therapeutics Reveals Preclinical ALLO-329 Data at ACR Convergence

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a biotechnology firm in the clinical development phase, is at the forefront of creating allogeneic CAR T (AlloCAR T™) therapies aimed at treating cancer and autoimmune disorders. The company unveiled preclinical findings related to ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy under assessment for autoimmune diseases. The results showcased at the American College of Rheumatology (ACR) Convergence 2024 indicate that ALLO-329 could effectively tackle significant obstacles linked to existing autologous CAR T cell treatments being developed for autoimmune patients, underscoring the potential benefits of an allogeneic CAR T approach in rebalancing the immune response.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

ALLO-329 is the inaugural CAR T therapy aimed at both CD19+ B cells and CD70+ activated T cells. The targeting of B cells has demonstrated the capability to produce long-lasting, treatment-free remissions in patients with specific autoimmune disorders. CD70 is found on activated T cells, which play a role in immune responses, including autoimmunity. The concurrent removal of CD70+ T cells may enhance therapeutic outcomes and broaden the range of indications that can be addressed.

CD70+ activated T cells also encompass alloreactive T cells, which are the patient’s own cells that can attack and reject an allogeneic CAR T therapy. ALLO-329 is engineered to effectively eliminate these alloreactive T cells, thereby making it resistant to rejection. The integration of Dagger® technology into ALLO-329 aims to minimize or eliminate the need for lymphodepletion prior to the infusion of cells.

Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene, stated, “The CAR T sector for autoimmune diseases is intensely competitive, with many strategies concentrating solely on specific facets of autoimmune pathogenesis. ALLO-329 distinguishes itself by addressing a broader range of immune dysfunction, targeting both B cells and activated T cells involved in the disease, which could lead to better disease outcomes with little to no lymphodepletion required. Additionally, its "off-the-shelf" availability positions ALLO-329 to satisfy the significant needs of a wide patient demographic. These preclinical results further amplify our enthusiasm as we advance this therapy into clinical trials for various autoimmune conditions.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of November 20, 2024, there are 5 investigational drugs for the CD70/CD19 target, including 8 indications, 5 R&D institutions involved, with related clinical trials reaching 5, and as many as 8659 patents.

The drug CD70/CD19 CAR T(Allogene Therapeutics) is a Universal CAR-T therapy that targets CD19 and CD70. It falls within the therapeutic areas of Neoplasms, Immune System Diseases, and Hemic and Lymphatic Diseases, with active indications for treating Lymphoma and Autoimmune Diseases.